Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $900.00 Price Target at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by Wells Fargo & Company from $1,050.00 to $900.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on REGN. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,037.33.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $696.88 on Friday. The company has a market cap of $76.58 billion, a PE ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a 52-week low of $691.00 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s 50 day moving average price is $751.44 and its 200-day moving average price is $962.58.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $39,000. Finally, Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $39,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.